New biologic option shown to reduce exacerbations and extend time to first flare
News
Bial launches new sublingual Parkinson’s treatment in UK
Sublingual apomorphine film offers rapid relief for OFF episodes
Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
First‑in‑class SK ion channel inhibitor enters next stage of clinical development
Johnson & Johnson seeks EMA approval for teclistamab–daratumumab combination
Company aims to expand treatment options for relapsed or refractory multiple myeloma
HUTCHMED begins phase 3 stage of pancreatic cancer trial
Combination therapy moves into late‑stage testing after encouraging earlier results
Zenas reports strong phase 3 results for obexelimab in IgG4-related disease
Company prepares regulatory filings after treatment shows significant reduction in disease flare risk
MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
MRM’s platform could optimise the link between the gut microbiome and cancer outcomes
Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
Arthrosi’s investigational gout treatment is currently being evaluated in global studies
Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
The two companies aim to reduce administrative burden and speed up drug delivery
Title21 Health Solutions joins the Blood and Cells Advocacy Roster
The blood industry plays a vital role in supporting the development of advanced therapies
NADMED launches $30,000 metabolomics research award
Winners will receive metabolomics kits, expert consultation and measurement services
eXmoor Pharma and UCL establish strategic cell and gene therapy collaboration
Cell and gene therapies are often delayed by technical and regulatory issues
Miranda Dini launches GOLD amid industry shifts
New consultancy aims to deliver personalised senior expertise in healthcare communications
Genfit reports promising phase 1b data in cholangiocarcinoma
Results show disease control and tumour shrinkage with GNS561 and MEK inhibitor combination
GRI Bio reports positive phase 2a data in idiopathic pulmonary fibrosis
Trial shows GRI-0621 improved lung function with signs of fibrosis resolution
